Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome

Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes

(2016) Anna Björquist et al.   THROMBOSIS AND HAEMOSTASIS

Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets

(2014) Isabella Massimi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

(2013) Robert F. Storey et al.   PLATELETS

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy

(2012) Deepak Voora et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes

(2010) Robert F. Storey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Stabilizing Role of Platelet P2Y12 Receptors in Shear-Dependent Thrombus Formation on Ruptured Plaques

(2010) Reyhan Nergiz-Unal et al.   PLoS One

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

(2009) Stefan James et al.   AMERICAN HEART JOURNAL

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE